PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Negative net income growth while TRAW stands at 15.38%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Slight usage while TRAW is negative at -133.70%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
AP growth well above TRAW's 113.11%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-34.25%
Both reduce yoy usage, with TRAW at -963.32%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
198.30%
Well above TRAW's 114.29%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
56.08%
Some CFO growth while TRAW is negative at -14.24%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth well above TRAW's 33.45%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
Investing outflow well above TRAW's 33.45%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
42.27%
Debt repayment growth of 42.27% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.